Abstract
The immunopathology of rheumatoid arthritis (RA) is now better understood, and this knowledge has been translated into more effective therapy with biologic response modifiers. The first group of biologic response modifiers are the tumor necrosis factor inhibitors. There efficacy in controlling RA has been such that remission is now the goal of RA management. As with any patient treatment, safety is an issue; patients will need ongoing monitoring for infections, tumors, and other rare complications.
Original language | English (US) |
---|---|
Pages (from-to) | 709-715 |
Number of pages | 7 |
Journal | Annals of the New York Academy of Sciences |
Volume | 1051 |
DOIs | |
State | Published - 2005 |
Keywords
- Biologic response modifiers
- Corticosteroids
- Disease-modifying antirheumatic drugs
- DMARDs
- Rheumatoid arthritis
- TNF-α inhibitors
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)